Effects of ezetimibe combination therapy for patients with atherosclerotic cardiovascular disease; randomized comparison of LDL-cholesterol targeting <70 versus <55mg/dL; Ez-PAVE trial

Yonsei University Health System, Severance Hospital0 个研究点目标入组 3,048 人开始时间: 待定最近更新: 2021年7月12日

适应症

试验速览

暂无简介。

•1. Age 19-80 years
•2. Documented atherosclerotic cardiovascular disease (ASCVD)
•A. Previous acute coronary syndrome (myocardial infarction [MI] or unstable angina),
•B. Or stable angina with imaging or functional studies
•C. Or coronary revascularization (percutaneous coronary intervention [PCI], coronary artery bypass graft [CABG], and other arterial revascularization procedures)
•D. Or stroke and transient ischemic attack (TIA)
•E. Or peripheral artery disease.

•1. LDL-cholesterol level less than 70 mg/dL without statin therapyAllergy or hypersensitive to ezetimibe or statin
•2. Active liver disease or persistent unexplained serum AST/ALT elevation more than 2 times the upper limit of normal range
•3. Allergy or hypersensitivity to any statin or ezetimibe
•4. Solid organ transplantation recipient
•5. Pregnant women, women with potential childbearing, or lactating women
•6. Life expectancy less than 3 years
•7. Inability to follow the patient over the period of 1 year after enrollment, as assessed by the investigator
•8. Inability to understand or read the informed content

发起方